home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

8th Annual Biomarkers Congress 2013

  February 04, 2013  
Oxford Global Conferences, Manchester
19th&20th February 2013

The Event

In keeping with Oxford Global’s highly successful life sciences series, an expert panel of over 50 speakers will present a full conference programme covering the topics outlined below:

8th Annual Biomarkers Congress

Day 1 Stream 1 –  Biomarker Discovery & Development

  • Biomarker assays
  • Open innovation initiatives
  • Analytical methods & applications
  • Biobanking
  • Regulatory strategy
  • Validation challenges

Day 1 Stream 2 – Companion Diagnostics & Personalised Medicine

  • Patient selection
  • Translating biomarkers into clinical diagnostics
  • Rx/Dx co-development
  • Biomarker based PHC
  • Diagnostic imaging
  • Prediction of treatment response

Day 2 Stream 1 – Biomarkers in Clinical Development

  • Biomarkers as surrogate endpoints
  • Circulating protein biomarkers
  • Safety & toxicity biomarkers
  • Biomarker integration
  • PK/PD markers
  • Clinical decision making

Day 2 Stream 2 – Enabling Technologies & Identification

  • Reducing attrition rates
  • Multiple reaction monitoring
  • Systems pharmacology modelling
  • Proteomics
  • Genomics & epigenomics
  • Metabolomics

2nd Annual CNS Biomarkers Congress

Day 1 –  CNS Biomarkers

  • Monitoring therapeutic efficacy
  • Human pain models
  • Neurobehavioural markers
  • Alzheimer’s disease
  • Fragile X syndrome
  • Autism

Day 2 – CNS Case Studies

  • Neuroimaging
  • Nuclear medicine
  • Cognitive function markers
  • Post traumatic stress disorder
  • MS & ALS
  • Schizophrenia
Organized by: Oxford Global Conferences
Invited Speakers:
  • Sameer Agarwal
    Senior Vice President, Business Center-Strategic Marketing IV Drugs, Fresenius Kabi
  • Balaji Agoram
    Director Clinical Pharmacology and Pharmacokinetics, MedImmune
  • Mads Almose Røpke
    Senior Scientist, LEO Pharma
  • Khusru Asadullah
    VP and Head of Global Biomarkers, Bayer Health Care
  • Till Bachmann
    Reader in Personalised Medicine in Infectious Diseases, Edinburgh University
  • Anne-Christine Bay-Jensen
    Principal Scientist, Head of Rheumatology, Nordic Bioscience
  • Christine Becker
    Head, Global Regulatory Affairs, Diagnostic Imaging,  Bayer
  • Mark Broenstrup
    Section Head Biomarker & Diagnostics, Sanofi Aventis
  • Miu Chau
    Global Head Companion Diagnostics Operations, Genentech
  • Paul Cutler
    Head of Mass Spectrometry, Roche
  • Andre De Costa
    Senior Scientist Safety Biomarkers, UCB
  • Varsha Desai
    Research Biologist, FDA
  • Lucette Doessegger
    Global Head Safety Licensing and Early Development, Roche
  • Michael E. Burczynski
    Executive Director, Integrated Biomarker Technologies, Bristol-Myers Squibb
  • Chris Harbron
    Senior Principal Statistician - Personalised Healthcare & Biomarkers, AstraZeneca
  • John Haselden
    Director & Head of Investigative Preclinical Toxicology, Safety Assessment, GSK R&D
  • Kim Henriksen
    Head of Neurodegenerative Diseases, Nordic Bioscience
  • Michael Herschel
    Director Clinical Research, GSK
  • Joerg Heyer
    Director Cancer Biology, AVEO Oncology
  • Heinz Hänel
    Professor, Diabetes Division, Sanofi
  • Marti Jett
    Director, Integrative Systems Biology, Chief Scientist, Systems Biology Enterprise US Army Medical Command (MEDCOM), US Army Center for Environmental Health Research
  • Sajan Khosla
    Principal Informatics Scientist, AstraZeneca
  • Gereon Lauer
    Associated Director Clinical Biomarkers, Vertex Pharmaceuticals (Europe) Ltd
  • Afrodite Lourbakos
    Director Bioanalysis & Biomarkers, Prosensa
  • Johan Luthman
    VP Neuroscience R&D, Franchise Integrator, Merck & Co
  • Hugh Marston
    Head of Pharmacology, TPP Global Development Ltd
  • Emilio Merlo Pich
    Head, CNS Biomarker & Clinical Imaging, F. Hoffmann-La Roche
  • Mehdi Mesri
    Program Manager, NIH / National Cancer Institute
  • Allison Nance
    Executive Director, Global Regulatory Affairs, Biomarkers/Diagnostics Development, Celgene Corporation
  • Pradeep Nathan
    Professor and Director of Neuroscience, GlaxoSmithKline
  • N R Nirmala
    Director, Biomarker Analysis and Informatics, Novartis Institutes for Biomedical Research
  • Tim Peakman
    Deputy CEO, UK Biobank & UK Biocentre
  • Darrel Pemberton
    Associate Director, Neuroscience Early Development, Janssen
  • Stephen Pennington
    Professor of Proteomics, School of Medicine and Medical Science, UCD Conway Institute, University College Dublin
  • Mark Pinches
    Biomarker Lead, Global Safety Assessment, AstraZeneca
  • Andrew Pitt
    Professor of Pharmaceutical Chemistry and Chemical Biology, Aston University
  • Jens Rengelshausen
    Head Translational Medicine Global Early Clinical Development, Grünenthal
  • Senior Representative
  • Sally-Ann Ricketts
    Director, In Vivo Biomarkers, AstraZeneca
  • Anthony Rowe
    Principal Research Scientist, Janssen Research and Development
  • Gemma Satterthwaite
    Director & Portfolio Lead, Personalised Healthcare and Biomarkers, Astrazeneca
  • Robert Schupp
    Executive Director Diagnostics Hematology/Oncology, Celgene
  • Kresten Skak
    Head of Section, LEO Pharma
  • Holly Soares
    Director Clinical Biomarkers Neruoscience, BMS
  • Corinne Solier
    Group Head, Clinical Protein Biomarkers, Roche Pharma
  • Hans Ulrichts
    Section Head Pharmacology – Pharmacodynamics and Translational Medicine, Ablynx
  • Alain Van Gool
    Head Biomarkers in Personalized Medicine, TNO
  • Eduardo Vianna
    Clinical Scientist, Roche
  • Anne Vogt
    Personalized Health Care Leader, Neuroscience, Roche
  • Richardus Vonk
    Head of Global Drug Discovery Statistics and Experimental Medicine Statistics, Bayer Pharma AG
  • Jill Walker
    Diagnostics Director, AstraZeneca
  • Susan Ward
    Sr. Clinical Program Lead, Translational and Experimental Medicine, Biogen
  • Andy West
    Biological Mass Spectrometry Section Head, GSK
  • Hans Westerhoff
    AstraZeneca Chair for Systems Biology, Professor of Synthetic Systems Biology, University of Amsterdam and University of Manchester
  • Paul Whittaker
    Director/Unit Head for Pre-Clinical Biomarkers, Respiratory Disease Area, Novartis
  • Sophie Wildsmith
    Biomarker Key Service Area Manager, Strategic Outsourcing, Roche
  • Doris-Ann Williams MBE
    Director-General, British In Vitro Diagnostics Association
  • John Wise
    Executive Director, Pistoia Alliance
Deadline for Abstracts: Filled

Registration is due to close. Book now at: http://ds4.delegateselect.co.uk/MT/Run/event/main.html?EC=147062&EEID=337865733793565136239212255&EGID=74152026904&override=shownewreg


E-mail: d.meredith@oxfordglobal.co.uk
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.